FDA ApprovedUnited States
First FDA-Approved Implant Treatment for MacTel Eye Disease
Encelto (revakinagene taroretcel-lwey) — encapsulated cell implant for macular telangiectasia type 2
FDA approval on 5 March 2025 for Encelto (revakinagene taroretcel-lwey) implant — an allogeneic encapsulated cell-based gene therapy for intravitreal surgical…
This is for adults living with idiopathic macular telangiectasia type 2 — and the caregivers who help them — who may be candidates for labelled US Encelto…